And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is particularly modest this time around. We hope to catch up on some reading, tidy up around the castle, and hang with our short person. And what about you? This remains a lovely time of year to enjoy the outdoors, although you may want to winterize your own castle. You could plan a holiday break. Or simply map out the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The U.S. Securities and Exchange Commission may have told Valeant Pharmaceuticals (VRX) to stop using non-standard earnings numbers in its regulatory filings, but the company is sending journalists the number anyway, MarketWatch reports. The regulator has been cracking down on the use of metrics that do not conform with Generally Accepted Accounted Principles, but that usually make results look better and can be misleading for investors.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy